Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2014, Vol 1, Issue 1
Abstract
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is well protected from development of liver cancer. However, the negative control of liver proliferation by these factors and other tumor suppressor genes is eliminated in liver cancer. Studies of liver regeneration after surgery and injury have provided fundamental mechanisms on how liver neutralizes tumor suppressor proteins for the time of regeneration; however, studies of liver cancer in animal models and in human samples showed several additional pathways of this neutralization. One of these additional pathways includes activation of a small subunit of the proteasome, Gankyrin. Gankyrin is dramatically increased in human hepatocellular carcinoma (HCC) and in animal models of carcinogenesis. Once activated Gankyrin triggers degradation of main tumor suppressor proteins during development of liver cancer using slightly different mechanisms. Recent studies identified mechanisms which repress Gankyrin in quiescent livers and mechanisms of activation of Gankyrin in liver cancer. These mechanisms involve a communication between Farnesoid X Receptor (FXR) signaling and chromatin remodelling proteins mediated by members of C/EBP family. It has been recently shown that C/EBPα plays a critical role in this network and that the activation of C/EBPα in cirrhotic livers with HCC inhibits cancer progression. This C/EBPαdependent inhibition of liver cancer involves activation of a majority of tumor suppressor genes and repression of tumor initiating pathways such as β-catenin and c-myc. These recent findings provide a background for FXR-based and C/EBPα-based approaches to treat liver cancer.
Authors and Affiliations
Nikolai A. Timchenko
Keywords
Related Articles
- EP ID EP552522
- DOI 10.17140/CSMMOJ-1-104
- Views 120
- Downloads 0
Gastrointestinal Stromal Tumors: Innovation from Diagnosis to Treatment Based on 15 Years of Experience of a Peripheral Hospital in Portugal
Aim: To investigate fifteen years of experience, in managing GISTs, according to best clinical practice, on a peripheral Portuguese Hospital. Define the behavior of GIST’s and the association between the histological, im...
Effects of Three Dimensional Microenvironment on Tumorigenicity of Fibrosarcoma in vitro
Tumor microenvironment plays an important role in cancer progression owing to interactions between the tumor and adjoining cells and, as in bone marrow, the unique architecture and chemical compounds that characterize it...
Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in comb...
Prostate Cancer Trends in Developing Countries
Prostate cancer is the commonest cancer in USA and most European Countries and is the 2nd commonest cancer among males globally. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, account...
The Emerging Role of p27 in Development of Diseases
The cell cycle regulation and tumor suppressor p27 encoded by CDKN1B plays a key role in many cellular events.1-3 p27 is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors, which functions to nega...